Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 2Down Syndrome 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

prednylidene 1pegaspargase 1merphos 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1blinatumomab 1azathiopurine 1auricularum 1asparaginase erwinia chrysanthemi recombinant 1Vincristine 1Thioguanine 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Calcium Dobesilate 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × azathiopurine × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡